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Edited by Laszlo NagyAbstract Stroke is characterized by massive inﬂammation in
areas surrounding the injury that magniﬁes damage to the brain.
The liver X receptors (LXRs) are nuclear receptors that regulate
cholesterol, lipid, and glucose metabolism. Synthetic LXR ago-
nists have potent anti-inﬂammatory properties in a variety of set-
tings, including neuroinﬂammation. However, the ability of LXR
agonists to suppress stroke-associated inﬂammation has not been
evaluated. Here, we have used time-lapse magnetic resonance
imaging (MRI) to show that a single dose of an LXR ligand
administered post-injury dramatically reduces brain damage in
a model of acute brain ischemia. Neuroprotection was associated
with suppression of neuroinﬂammation.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Every year, close to a million people in the US alone suﬀer a
stroke [1]. A ﬁfth of them die from the episode and a large pro-
portion of survivors are left with permanent mental and phys-
ical disabilities. During stroke, irreversible neuronal injury
occurs only in a small area [2]. A much larger volume of the
brain surrounding this ischemic core can be salvaged if cere-
bral blood ﬂow is promptly restored. Tissue survival is deter-
mined by a variety of cell growth, survival, and death signals
emanating from multiple cell types. Current therapies for
stroke consist primarily of ﬁbronilytic agents such as tPA,
and surgery, though only a fraction of patients are eligible
for these treatments. In addition, anticoagulants are typically
used to prevent recurrence of stroke. A dire need exists to dis-
cover new treatments for stroke and to minimize its sequela.
Recently, anti-inﬂammatory agents such as indomethacin haveAbbreviations: LXR, liver X receptor; ABCA1, ATP-binding cassette
A1; SREBP, sterol regulated-element binding protein; MRI, magnetic
resonance imaging
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doi:10.1016/j.febslet.2008.08.035shown promise to restraint inﬂammation during a stroke,
enhancing neurogenesis and tissue repair [3]. Hence, agents
that can curtail neuroinﬂammation may have utility in the
treatment of stroke.
The LXRs (LXRa and LXRb) are ligand-activated tran-
scription factors of the nuclear receptor superfamily that regu-
late cholesterol, lipid, and glucose metabolism [4]. Synthetic
LXR ligands have beneﬁcial eﬀects in animal models of athero-
sclerosis, diabetes, and various diseases with an inﬂammatory
component [5]. LXRa is primarily expressed in liver, fat, mac-
rophages, and to some extent in the brain. In contrast, LXRb
is broadly expressed across tissues and is highly expressed in
brain. Recent studies have shown that the LXRs regulate brain
cholesterol homeostasis, and that synthetic LXR agonists can
ameliorate the functional deﬁcits associated with Alzheimers
disease, perhaps via their ability to modulate cholesterol
metabolism and suppress neuroinﬂammation [6–8]. These ﬁnd-
ings prompted us to examine the eﬀect of LXR ligands in acute
models of stroke.2. Materials and methods
2.1. Animal experiments
Male Sprague–Dawley rats underwent permanent MCAO as pre-
viously described [9,10] and were treated 10 min or 2 h later with
vehicle or a single dose of GW3965 (20 mpk i.p.) (n = 8/group).
Magnetic resonance imaging (MRI) measurements were performed
2, 24 and 48 h after MCAO using a 4.7T vertical superwidebore
magnet of a Bruker AvanceII spectrometer with micro imaging
accessory. Animal preparation, image acquisition, trace of the diﬀu-
sion tensor [Tr(D)] map computation, ischemic volume determina-
tion, and progression of the ischemic damage over time was done
as described in reference [14]. The experiment was performed twice
(n = 16 total/group) with identical results. Animal procedures were
approved by the Department of Pharmacological Sciences, Univer-
sity of Milan.
2.2. Gene expression analysis
RNA from the indicated frozen brain sections was prepared using
Nucleospin 96 RNA kits (Macherey-Nagel, Germany). Gene expres-
sion was analyzed by TaqMan qRT-PCR using the one-step Super-
script III platinum reagent (Invitrogen, Carlsbad, CA). Samples were
run in triplicate as multiplexed reactions with a normalizing internal
control (36B4). Probe and primer sequences were designed in-house
or obtained as pre-made Gene Expression Assays from ABI (Foster
City, CA). Sequences for assays designed in-house are available on re-
quest. Statistical analysis was performed by using a two-tailed Stu-
dents t-test.blished by Elsevier B.V. All rights reserved.
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Neurological deﬁcits were evaluated using the foot fault, Bederson,
and De Ryck tests, as previously detailed [11]. Tests were repeated 24
and 48 h after MCAO in rats treated either with vehicle or with
GW3965 at 2 or 6 h after ischemic insult. Statistical diﬀerences were
evaluated with a Mann–Whitney test.3. Results
To evaluate the eﬀect of synthetic LXR ligands in stroke, we
used the middle cerebral artery occlusion (MCAO) rat model,
a well-established model to evaluate neuroprotective eﬀects
after focal cerebral ischemia. This model has been widely used
to assess the ability of compounds such as glucocorticoids,
indomethacin, statins, and others to reduce infarct volume
and enhance post-injury neurogenesis [3,9,12–14]. Time-lapse
non-invasive MRI was used to monitor the evolution of brain
lesions in rats where focal cerebral ischemia was induced by
permanent middle cerebral artery occlusion. This technique en-
ables evaluation of onset, progression, and outcome of brain
damage within the same animal. Male Sprague–Dawley rats
underwent monolateral permanent middle cerebral artery
occlusion and were treated 10 min later with either vehicle orb
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Fig. 1. LXR ligands block ischemia-induced brain damage. (a) Male rats un
dose of GW3965 (20 mpk i.p.) (n = 8/group). Infarct volume was monitored
animal visualized at three diﬀerent time points; three representative rats per
ischemic damage over time was evaluated by ANOVA. For each animal, the
extension of ischemic area at all other time points was proportionally calculat
Progression of ischemic damage in rats treated with LXR ligand 2 h post-inj
complete protection. Data are expressed as mean values ± S.E.M.; *P < 0.05a single dose of the LXR ligand GW3965 (20mpk i.p.). MRI
of developing damage, detected as hypointense areas in the
cerebral cortex, showed that in vehicle treated rats (n = 8),
brain infarct volume in the injured hemisphere increased sig-
niﬁcantly between 2 and 48 h post-MCAO (Fig. 1a). In con-
trast, treatment with the LXR agonist post-injury (n = 8)
completely prevented increase of damage at 24 and 48 h. The
infarct volume area in LXR-ligand-treated animals at 2 and
48 h remained the same, indicating that LXR activation in this
model of stroke has dramatic neuroprotective eﬀects (Fig. 1b).
Identical results were obtained when the LXR ligand was
administered 2 h post-injury, which suggests that the therapeu-
tic window for treatment with LXR activators may be clini-
cally useful (Fig. 1c). Treatment with a single dose of LXR
agonist after ischemic injury improved sensorimotor function
recovery (De Ryck test), and the ability of the animals to inte-
grate motor response (foot fault test). A positive trend was ob-
served also in the postural reﬂex test of Bederson (Fig. 2).
To explore the mechanism of neuroprotection of LXR
ligands, we evaluated expression of pro-inﬂammatory genes
in the brain. Analysis of gene expression in the ipsilateral
and controlateral areas of the striatum and of the cortex har-
vested from treated rats at 24 h showed that pro-inﬂammatoryGW3965
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ischemic area at 2 h after ischemia induction was set to 100%, and the
ed, thus providing an internal control of ischemia development [12]. (c)
ury. Note that at this time point the LXR ligand continues to provide
, **P < 0.01.
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Fig. 2. Treatment with LXR ligands reduces stroke-induced neurological deﬁcits. Neurological deﬁcits were evaluated by the De Ryck, Bederson,
and foot fault tests in rats receiving vehicle or GW3965 administered 2 or 6 h after ischemic insult. Tests were performed at 24 h (white columns) and
48 h (black columns) after MCAO. Statistical diﬀerences were evaluated with a Mann–Whitney test. Data are expressed the mean score of 5 rats;
&P < 0.05 vs. vehicle at 48 h; *P < 0.05 vs vehicle at 24 h; **P < 0.01 vs. vehicle at 24 h; #P < 0.05 vs. vehicle at 48 h.
Fig. 3. Gene expression analysis post-MCAO. Tissues from rats (n = 5) treated as in Fig. 1a were harvested at 24 h and gene expression analyzed by
TaqMan-based qRT-PCR. White bars (vehicle), black bars (GW3965). Ipl, ipsilateral; Col, controlateral. Data are expressed as mean values ± S.D.
*P < 0.05, **P < 0.01. Statistical analysis was performed by using a two-tailed Students t test.
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Fig. 4. Immune cell recruitment. Rats treated 10 min after MCAO
with vehicle or GW3965 were sacriﬁced 72 h after induction of
damage. Paraﬃn-embedded brain sections were stained with an
antibody against ED1 (Serotec, Oxford UK) that detects macro-
phage/monocyte inﬁltration, and examined by light microscopy. ED1
positive cells were counted in the ipsilateral hemisphere to damage in
four diﬀerent coronal brain slices from six diﬀerent animals.
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strongly upregulated in the ipsilateral part, the damaged area,
especially in the cortex (Fig. 3) conﬁrming that this is the area
most aﬀected by ischemia, as can be seen in Fig. 1a. The single
dose treatment with the LXR ligand virtually abolished in-
crease in expression of all pro-inﬂammatory genes induced
by ischemia. This dramatic eﬀect of GW3965 was not observed
in genes whose expression was not aﬀected by the injury. The
reduction in expression of pro-inﬂammatory markers was re-
ﬂected in a clear but not statistically signiﬁcant decrease in
the number of ED1 positive cells (present in activated macro-
phages and microglia), suggesting that LXR activation may in-
hibit recruitment of immune cells (Fig. 4). In addition to their
anti-inﬂammatory properties, the LXRs are also known to reg-
ulate expression of vascular endothelial growth factor (VEGF)
in macrophages [15]. Because VEGF has been shown to reduce
infarct size and improve functional outcome after experimental
cerebral brain ischemia [16,17], we examined the expression of
VEGF in rats treated with the LXR agonist. Expression of
both VEGF-A and VEGF-B was increased in response to
GW3965 throughout the brain, suggesting that induction of
VEGF expression may contribute to the neuroprotective ef-
fects of LXR activation (Fig. 3). Expression of direct LXRs
target genes, such as ATP-binding cassette A1 (ABCA1) and
SREBP-1c, was increased after GW3965 treatment in all areas
harvested, conﬁrming the eﬃcacy of ligand delivery. Ischemic
injury did not result in any signiﬁcant changes in mRNA
expression for either LXR isoform (data not shown).4. Discussion
Previous work has established that LXR ligands attenuate
inﬂammatory responses in macrophages, suppressing expres-
sion of inﬂammatory genes induced by pathogens and pro-
inﬂammatory cytokines, such as interleukin 1b (IL-1b), cyclox-
ygenase-2 (COX2), inducible nitric oxide synthase (iNOS),
interleukin 6 (IL-6), monocyte chemoattractant protein-1
(MCP-1), and matrix metalloprotease 9 (MMP-9) [5,18,19].The mechanism whereby LXR ligands suppress pro-inﬂamma-
tory gene expression is thought to involve SUMOylation of the
LXRs, and interference of ligand-activated LXRs with NF-jB
signaling, a critical pathway for the inﬂammatory response
[20–22]. More recently, it has been shown that LXR agonists
can restrain the response of primary microglia and primary
astrocytes to inﬂammatory stimuli such as lipopolysaccharide
(LPS) and ﬁbrils of b-amyloid protein [8,23]. Given the estab-
lished role of many of these pro-inﬂammatory genes in the
pathogenesis of cerebral ischemia, we decided to examine the
neuroprotective potential of synthetic LXR agonists in exper-
imental stroke.
In contrast to previous studies in a variety of settings that
demonstrated anti-inﬂammatory properties of LXR ligands
primarily in prophylactic mode, we have found that a single
dose of an LXR agonist delivered 2 h post-injury can eﬀec-
tively block ischemia-induced brain damage. Using time-lapse
MRI to evaluate brain damage within the same animal, we
have shown that LXR activation can dramatically ameliorate
the extent of cytotoxic edema that results from ischemic insult.
LXR activation may reduce infarct size by restraining neuroin-
ﬂammation, and promoting VEGF expression. Because there
are several synthetic LXR ligands in clinical development,
our ﬁndings suggest that LXR activation may constitute a
novel approach to minimize stroke-induced brain damage.
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